Resources from the same session
Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial
Presenter: Sian Pugh
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?
Presenter: Jemma Bhoday
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Presentation
Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
Presenter: Eric Van Cutsem
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Presentation
Invited discussant abstracts 454O, 455O and LBA20
Presenter: Volker Heinemann
Session: Gastrointestinal tumours, colorectal 1
Resources:
Presentation
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)
Presenter: Ryan Corcoran
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Presentation
A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial
Presenter: Derek Jonker
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract